Dermatosis is a condition wherein the skin dermis, hair, nail, etc has an irritation or an anomaly. Corticosteroids are usually used to treat inflammation, but it is observed that corticosteroids sometimes also helped alleviate dermatoses. Corticosteroids, besides their inflammation control action are useful in treating disorders that are caused by hyperactivity of the immune response. Corticosteroids' has side effects, such as allergic responses. Corticosteroids are to be used as a topical ointment only in skin regions with inflammation. Globally, development of new technology, rise in the demand for corticosteroid-responsive dermatoses, and increasing government initiative are the prime growth drivers of global corticosteroid-responsive dermatoses market. In addition, increase in adoption of corticosteroid-responsive dermatoses, and emerging economies such as China, India and others, will create new opportunities for global corticosteroid-responsive dermatoses market. However, higher cost of research and development, and harmful side effects are the key restraints for global corticosteroid-responsive dermatoses market.
Number of Products under Development for Corticosteroid-Responsive Dermatoses, H1 2014 7
Number of Products under Development for Corticosteroid-Responsive Dermatoses - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 17
Number of Products by Stage and Top 10 Target, H1 2014 18
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 19
Number of Products by Top 10 Route of Administration, H1 2014 20
Number of Products by Stage and Top 10 Route of Administration, H1 2014 21
Number of Products by Stage and Top 10 Molecule Type, H1 2014 22
AB - Background: Corticosteroids (CS) may benefit certain patients with erythromelalgia. Objectives: Our objective was to determine clinical predictors of corticosteroid-responsive erythromelalgia. Methods: Patients with erythromelalgia who received CS were identified and stratified into corticosteroid nonresponders (NRs), partial corticosteroid responders (PSRs), complete corticosteroid responders (CSRs), and steroid responders (SRs = PSRs + CSRs). In the study variable analysis, . P < .05 was considered statistically significant. Results: The median (interquartile range) age of the 31-patient cohort was 47 years (26-57 years), and 22 (71%) were female. Fourteen (45%) were NRs, 17 (55%) SRs, 8 (26%) PSRs, and 9 (29%) CSRs. A subacute temporal profile to disease zenith (<21 days) was described in 15 (48%) patients, of whom 13 (87%) were SRs (P = .003; odds ratio [OR] = [95% confidence interval CI, -]). Six (67%) CSRs reported a disease precipitant (eg, surgery, trauma, or infection; . P = .007; OR = [95% CI, 2-]). SR patients received CS sooner than NR at 3 (3-12) versus 24 (17-45) months (P = .003). A high-dose CS trial (≥200 mg prednisone cumulatively) was administered to 17 (55%) patients, of whom 13 (76%) were SRs (P = .012; OR = [95% CI, -]). Limitations: This was a retrospective case series. Conclusion: An infectious, traumatic, or surgical precipitant and subacute presentation may portend CR erythromelalgia. A transient "golden window" where CS intervention is useful may exist before irreversible nociceptive remodeling and central sensitization occurs.